Tenax Therapeutics, Inc. (TENX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tenax Therapeutics, Inc. on December 17, 2025. The filing reports significant clinical trial developments regarding the Company's lead candidate, TNX-103 (oral levosimendan), for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial milestones and does not contain financial statements or operational financial data.
Material Changes and Clinical Updates
- LEVEL Trial BSSR Results: The prespecified Blinded Sample Size Re-estimation (BSSR) for the ongoing Phase 3 LEVEL trial demonstrated the study is powered at well over 90% to detect a 25-meter change in 6-minute walk distance (6MWD), the primary endpoint.
- Enrollment Confirmation: Based on the BSSR results, the Company confirmed its previously announced target enrollment number, expected enrollment completion timeframe, and topline data timeframe.
- New Study Initiation: The Company announced the initiation of the global Phase 3 LEVEL-2 study, which serves as the second registrational Phase 3 study of TNX-103 in patients with PH-HFpEF.
Outlook and Management Commentary
Management confirmed that the statistical power of the LEVEL trial supports the current development timeline. The initiation of the LEVEL-2 study indicates the Company is proceeding with its dual registrational strategy for TNX-103 in the PH-HFpEF indication. No specific risks or contingencies were detailed in the text of this filing beyond the inherent uncertainties of clinical development.
Investor Verification Checklist
- Verify the specific target enrollment numbers and topline data dates referenced in the attached press release (Exhibit 99.1).
- Confirm the detailed protocol and inclusion criteria for the newly initiated LEVEL-2 study.
- Review the Company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not contain financial data.
- Monitor upcoming investor presentations for updates on the statistical methodology used in the BSSR analysis.